Overview

A Study To Evaluate the Relative Bioavailability, Food Effect, and Dose Proportionality of a Granule Formulation of Vanzacaftor/Tezacaftor/Deutivacaftor(VNZ/TEZ/D-IVA)

Status:
COMPLETED

Trial end date:
2024-05-23

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the relative bioavailability, food effect, and dose proportionality of a granule formulation of VNZ/TEZ/D-IVA.

Phase:

PHASE1

Details

Lead Sponsor:

Vertex Pharmaceuticals Incorporated

Treatments:

deutivacaftor, tezacaftor , vanzacaftor